<- Go Home
enGene Holdings Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.
Market Cap
$655.1M
Volume
141.5K
Cash and Equivalents
$50.2M
EBITDA
-$122.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$12.25
52 Week Low
$2.65
Dividend
N/A
Price / Book Value
3.03
Price / Earnings
-4.26
Price / Tangible Book Value
3.03
Enterprise Value
$493.2M
Enterprise Value / EBITDA
-4.06
Operating Income
-$123.2M
Return on Equity
53.28%
Return on Assets
-28.90
Cash and Short Term Investments
$193.7M
Debt
$31.8M
Equity
$167.7M
Revenue
N/A
Unlevered FCF
-$58.5M
Sector
Biotechnology
Category
N/A